Trastuzumab emtansine

TypeName: Business Offer

Category:

Offer Date:2019/06/10

Country: United States

Summary: Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surface surfaces. Upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.https://www.bocsci.com/trastuzumab-emtansine-cas-1018448-65-1-item-465350.html

Description:

OfferId: 4485

Name:Alex Brown

Telphone:

Email:[email protected]

No Man

Trastuzumab emtansine

Advertising